Application of a combined 'effect compartment/indirect response model' to the central nervous system effects of tiagabine in the rat

Journal of Pharmacokinetics and Biopharmaceutics

Volumn 27, Issue 3, 1999, Pages 301-323

  Cleton, Adriaan ^a   De Greef, Henrik J M M ^a   Edelbroek, Peter M ^b,c   Voskuyl, Robert A ^b,c   Danhof, Meindert ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b STICHTING EPILEPSIE INSTELLINGEN NEDERLAND SEIN   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Effect compartment model; GABA uptake inhibitor; Indirect response; Pharmacodynamics; Pharmacokinetics; Sigmoid E(max); Tiagabine

Indexed keywords

TIAGABINE;

ARTICLE; BLOOD SAMPLING; CENTRAL NERVOUS SYSTEM; COMPARTMENT MODEL; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG INHIBITION; DRUG STRUCTURE; ELECTROENCEPHALOGRAM; GABAERGIC TRANSMISSION; MALE; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL; RAT; STEADY STATE;

EID: 0033501265     PISSN: 0090466X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020999114109     Document Type: Article

References (36)

1. 1. P. Krogsgaard-Larsen. Inhibitors of the GABA uptake systems. Mol. Cel. Biochem. 31:105-121(1980).
2. 2. P. Krogsgaard-Larsen, O. M. Larsson, and A. Schousboe, GABA uptake inhibitors: relevance to antiepileptic drug research. Epileps. Res. 1:77-93 (1987).
3. 3. F. E. Ali, W. E. Bondinell, P. A. Dandridge, J. S. Frazee, E. Garvey, G. R. Girard, C. Kaiser, T. W. Ku, J. J. Lafferty, G. I. Moonsammy, H.-J. Oh, J. A. Rush, P. E. Setler, O. D. Stringer, J. W. Venslavsky, B. W. Volpe, L. M. Younger, and C. L. Zirke. Orally active and potent inhibitors of gamma-aminobutyric acid uptake. J. Med. Chem. 28:653-660 (1985).
4. 4. C. Braestrup, E. B. Nielsen, U. Sonnewald, L. J. S. Knutsen, K. E. Andersen, J. A. Jansen, K. Frederiksen, P. H. Andersen, A. Mortensen, and P. Suzdak. (R)-N-[4,4-Bis(3-Methyl-2-thienyl)but-3-en-1-yl]Nipecotic acid binds with high affinity to the brain γ-aminobutyric acid uptake carrier. J. Neurochem. 54:639-647 (1990).
5. 5. P. Suzdak and J. A. Jansen. A review of the preclinical pharmacology of tiagabine: a potent and selective anticonvulsant GABA uptake inhibitor. Epilepsia 36:612-626 (1995).
6. 6. W. J. Jusko and H. C. Ko. Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clin. Pharmacol. Ther. 56:406-419 (1994).
7. 7. N. L. Dayneka, V. Garg, and W. J. Jusko. Comparison of four basic models of indirect pharmacodynamic responses. J. Pharmacokin. Biopharm. 21:457-478 (1993).
8. 8. L. B. Sheiner, D. R. Stanski, S. Vozeh, R. D. Miller, and J. Ham. Simultaneous modelling of pharmacokinetics and pharmacodynamics: Application to d-tubocurarine. Clin. Pharmacol. Ther. 25:358-371 (1979).
9. 9. R. Nagashima, R. A. O'Reilly, and G. Levy. Kinetics of pharmacologic effects in man: the anticoagulant action of warfarin. Clin. Pharmacol. Ther. 10:22-35 (1969).
10. 10. Z.-X. Xu, Y.-N. Sun, D. C. DuBois R. R. Almon, and W. J. Jusko. Third-generation model for corticosteroid pharmacodynamics: roles of glucocorticoid receptor mRNA and tyrosine aminotransferase mRNA in rat liver. J. Pharmacokin. Biopharm. 23: 163-181 (1995).
11. 11. G. L. Levy. Mechanism-based pharmacodynamic modelling. Clin. Pharmacol. Ther. 56:356-357 (1994).
12. 12. D. Verotta and L. B. Sheiner. A general conceptual model for non-steady state pharmacokinetic/pharmacodynamic data. J. Pharmacokin. Biopharm. 23:1-4 (1995).
13. 13. W. J. Jusko, H. C. Ko, and W. F. Ebling. Convergence of direct and indirect pharmacodynamic response models. J. Pharmacokin. Biopharm. 23:5-8 (1995).
14. 14. D. Verotta and L. B. Sheiner. Rejoinder. J. Pharmacokin. Biopharm. 23:9-10 (1995).
15. 15. J. W. Mandema and M. Danhof. Pharmacokinetic-pharmacodynamic modelling of the central nervous system effects of heptabarbital using aperiodic EEG analysis. J. Pharmacokin. Biopharm. 18:459-481 (1990).
16. 16. L. E. Gustavson and S.-Y. Chu. High performance liquid Chromatographic procedure for the determination of tiagabine concentrations in human plasma using electrochemical detection. J. Chrom. 574: 313-318 (1992).
17. 17. R. C. Schoemaker and A. F. Cohen. Estimating impossible curves using NONMEM. Br. J. Clin. Pharmacol. 42:283-290 (1996).
18. 18. S. L. Beal and L. B. Sheiner (eds.). NONMEM users guide, NONMEM project group, University of California, San Francisco, CA (1992).
19. 19. H. Akaike. A new look at the statistical model identification. IEEE Transactions on Automat. Control 19:716-723 (1974).
20. 20. M. Gibaldi and D. Perrier. Non-compartmental analysis based on statistical moment theory. In Pharmacokinetics (2nd ed.), Marcel Dekker, New Yorkm 1982, pp. 409-424.
21. 21. A. Fink-Jensen, P. D. Suzdak, M. D. B. Swedberg, M. E. Judge, L. Hansen, and P. G. Nielsen. The γ-aminobutyric acid (GABA) uptake inhibitor, tiagabine, increases extracellular brain levels of GABA in awake rats. Eur. J. Pharmacol. 220:197-201 (1992).
22. 22. M. Lancel, J. Faulhaber, and R. A. Deisz. Effect of the GABA uptake inhibitor tiagabine on sleep and EEG power spectra in the rat. Br. J. Pharmacol. 123:1471-1477 (1998).
23. 23. A. M. L. Coenen, E. H. M. Blezer, and V. Luijtelaar. Effects of the GABA uptake inhibitor tiagabine on electroencephalogram, spike-wave discharges and behaviour of rats. Epilepsy Res. 21:89-94 (1995).
24. 24. L. B. Sheiner and D. Verotta. Further notes on physiological indirect response models. Clin. Pharmacol. Ther. 58:238-240 (1995).
25. 1 receptor agonists. J. Pharmacokin. Biopharm. 25:713-730 (1997).
26. 26. E. Snoeck, V. Pitrovskij, P. Jacqmin, A. Van Peer, M. Danhof, K. Ver Donck, R. Woestenborghs, H. Van Belle, L. Van Bortel, R. Van Gool, A. Dupont, and J. Heykants. Population analysis of the nonlinear red blood cell partitioning and the concentration-effect relationship of draflazine following various infusion rates. Br. J. Clin. Pharmacol. 43:603-612 (1997).
27. 27. E. Snoeck, K. Ver Donck, P. Jacqmin, H. Van Belle, A. G. Dupont, A. Van Peer, and M. Danhof. Physiological red blood cell kinetic model to explain the apparent discrepancy between adenosine breakdown inhibition and nucleoside transport occupancy of draflazine. J. Pharmacol. Exp. Ther. 286:142-149 (1998).
28. 28. J. C. Rekling, H. Jahnsen, and A. M. Laursen. The effect of two lipophilic γ-aminobutyric acid uptake blockers in CA1 of the rat hippocampal slice. Br. J. Pharmacol. 99:103-106 (1990).
29. 29. C. H. Davies, S. N. Davies, and G. L. Collingridge. Paired-pulse depression of mono-synaptic GABA-mediated inhibitory post-synaptic responses in rat hippocampus. J. Physiol. 424:513-531 (1990).
30. 30. S. M. Thompson and B. H. Gähwiler. Effects of the GABA uptake inhibitor tiagabine on inhibitory synaptic potentials in rat hippocampal slice cultures. J. Neurophysiol. 67:1698-1701 (1992).
31. 31. A. Cleton, R. A. Voskuyl, and M. Danhof. Adaptive changes in the pharmacodynamics of midazolam in different models of epilepsy: kindling, cortical stimulation, genetic absence epilepsy. Br. J. Pharmacol. 125:615-620 (1998).
32. 32. J. W. Mandema, E. Tukker, and M. Danhof. Pharmacokinetic-pharmacodynamic modelling of the EEG effects of midazolam in individual rats: influence of rate and route of administration. Br. J. Pharmacol. 102:663-668 (1991).
33. 33. A. Wessén, K. Parivar, M. Widman, A. Nilsson, and P. Hartvig. Concentration-effect relationships of eltanolone given as a bolus dose or constant rate intravenous infusion to healthy male volunteers. Anesthesiology 84:1317-1326 (1996).
34. 34. A. Patat, F. le Coz, C. Dubruc, J.-M. Gandon, G. Durrieu, I. Cimarotsi, S. Jezequil, O. Curet, I. Zieleniuk, H. Allain, and P. Rosenzwieg. Pharmacodynamics and pharmacokinetics of two dosage regimens of befloxatone, a new reversible and selective monoamine oxidase inhibitor, at steady state in healthy volunteers. J. Clin. Pharmacol. 36:216-229 (1996).
35. 35. E. H. Cox, T. Kerbusch, P. H. van der Graaf, and M. Danhof. Pharmacokinetic-pharmacodynamic modelling of the EEG effect of synthetic opioids in the rat: correlation with the interaction at the μ-opioid receptor. J. Pharmacol. Exp. Ther. 284:1095-1103 (1998).
36. 36. T. Rydberg, A. Jönsson, M. O. Karlsson, and A. Melander. Concentration-effect relations of glibenclamide and its active metabolites in human: modelling of pharmacokinetics and pharmacodynamics. Br. J. Clin. Pharmacol. 43:373-381 (1997).